Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.61
-0.06 (-0.69%)
May 26, 2026, 4:00 PM EDT - Market closed
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
130
Market Cap
521.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Rigel Pharmaceuticals | 299.77M |
| Ginkgo Bioworks Holdings | 151.40M |
| Assembly Biosciences | 71.10M |
| Prothena Corporation | 57.94M |
| XOMA Royalty | 48.56M |
| Prime Medicine | 4.03M |
| ProKidney | 889.00K |
KYTX News
- 7 days ago - Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 8 days ago - Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed - TheFly
- 8 days ago - Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - GlobeNewsWire
- 12 days ago - Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright - TheFly
- 12 days ago - Kyverna Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan - TheFly
- 14 days ago - Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c) - TheFly
- 14 days ago - Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results - GlobeNewsWire